The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Open accessAbstract
OBJECTIVE: To evaluate the effect of secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic changes through 2 years in patients with ankylosing spondylitis (AS). METHODS: In the phase III MEASURE 1 study, patients were randomised to receive intravenous secukinumab 10 mg/kg (at baseline, week 2 and week 4) followed by subcutaneous secukinumab 150 mg (intravenous 150 mg; n=125) or 75 mg (intravenous 75 mg; n=124) every four weeks, or matched placebo (n=122). Placebo-treated patients were re-randomised to subcutaneous secukinumab 150 or 75 mg from week 16. Clinical efficacy assessments included Assessment of SpondyloArthritis international Society 20 (ASAS20) response rates through week 104. Radiographic changes at week 104 were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). RESULTS: 97 (77.6%) and 103 (83.1%) patients in the intravenous 150 mg and intravenous 75 mg groups, respectively, completed week 104. In the full analysis set (intent-to-treat), ASAS20 response rates at week 104 were 73.7% and 68.0% in the intravenous 150 mg and intravenous 75 mg groups, respectively. Among patients with evaluable X-rays who were originally randomised to secukinumab (n=168), mean change in mSASSS from baseline to week 104 was 0.30±2.53. Serious adverse events were reported in 12.2% and 13.4% of patients in the 150 mg and 75 mg groups, respectively. CONCLUSIONS: Secukinumab improved AS signs and symptoms through 2 years of therapy, with no unexpected safety findings. Data from this study suggest a low mean progression of spinal radiographic changes, which will need to be confirmed in longer-term controlled studies. TRIAL REGISTRATION NUMBER: NCT01358175.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Sieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos-Vargas, R., Dougados, M., Hermann, K.-G., Landewé, R., Maksymowych, W., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.104018 · Cited by 1,652
Self-citationIL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
Sherlock, J. P., Joyce-Shaikh, B., Turner, S. P., Chao, C.-C., Sathe, M., Grein, J., Gorman, D. M., Bowman, E. P., McClanahan, T. K., Yearley, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2817 · Cited by 1,060
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505066 · Cited by 1,029
Self-citation2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., Dagfinrud, H., Dijkmans, B., Dougados, M., Emery, P., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151027 · Cited by 987
Self-citationvan der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
Self-citationvan der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., & Braun, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20852 · Cited by 860
Self-citationDougados, M., & Baeten, D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60071-8 · Cited by 780
Self-citation
Cited by
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Ramiro, S., Nikiphorou, E., Sepriano, A., Ortolan, A., Webers, C., Baraliakos, X., Landewé, R. B. M., Van den Bosch, F. E., Boteva, B., Bremander, A., et al. (2023) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223296 · Cited by 992
Self-citationAnkylosing spondylitis: etiology, pathogenesis, and treatments
Zhu, W., He, X., Cheng, K., Zhang, L., Chen, D., Wang, X., Qiu, G., Cao, X., & Weng, X. (2019) · Bone Research · doi:10.1038/s41413-019-0057-8 · Cited by 502
Ruiz de Morales, J. M. G., Puig, L., Daudén, E., Cañete, J. D., Pablos, J. L., Martín, A. O., Juanatey, C. G., Adán, A., Montalbán, X., Borruel, N., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102429 · Cited by 338
Mease, P., van der Heijde, D., Landewé, R., Mpofu, S., Rahman, P., Tahir, H., Singhal, A., Boettcher, E., Navarra, S., Meiser, K., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212687 · Cited by 303
Self-citationParadoxical gastrointestinal effects of interleukin-17 blockers
Fauny, M., Moulin, D., D'Amico, F., Netter, P., Petitpain, N., Arnone, D., Jouzeau, J.-Y., Loeuille, D., & Peyrin-Biroulet, L. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217927 · Cited by 261
Metadata
- Authors
- Braun, J., Baraliakos, X., Deodhar, A., Baeten, D., Sieper, J., Emery, P., Readie, A., Martin, R., Mpofu, S., & Richards, H. B.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 76
- Issue
- 6
- Pages
- 1070-1077
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2564945411
- Cited by
- 273
- References
- 40
- FWCI
- 32.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. https://app.cochat.ai/papers/10.1136/annrheumdis-2016-209730
- The paper
- Braun, J., Baraliakos, X., Deodhar, A., Baeten, D., Sieper, J., Emery, P., Readie, A., Martin, R., Mpofu, S., & Richards, H. B. (2017). Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2016-209730
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.